Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Tomas Cihlar and Danielle Porter.
Tomas Cihlar
Connection Strength
0.340
Danielle Porter
  1. Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. Cell Rep. 2021 07 27; 36(4):109450.
    View in: PubMed
    Score: 0.060
  2. Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir. Antiviral Res. 2021 04; 188:105033.
    View in: PubMed
    Score: 0.058
  3. Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent. Antimicrob Agents Chemother. 2021 01 20; 65(2).
    View in: PubMed
    Score: 0.058
  4. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep. 2020 07 21; 32(3):107940.
    View in: PubMed
    Score: 0.056
  5. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020 09; 585(7824):273-276.
    View in: PubMed
    Score: 0.055
  6. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 01 10; 11(1):222.
    View in: PubMed
    Score: 0.054
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.